Nevro (NYSE:NVRO - Get Free Report) released its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.15, Zacks reports. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The business had revenue of $105.55 million for the quarter, compared to analyst estimates of $102.61 million.
Nevro Trading Down 0.3 %
Shares of NYSE NVRO traded down $0.02 during midday trading on Friday, reaching $5.78. The stock had a trading volume of 497,325 shares, compared to its average volume of 664,323. The firm has a market cap of $216.40 million, a price-to-earnings ratio of -3.06 and a beta of 0.94. Nevro has a twelve month low of $3.17 and a twelve month high of $15.98. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. The company's 50 day moving average price is $4.97 and its 200 day moving average price is $4.94.
Analysts Set New Price Targets
NVRO has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $7.00 price target on shares of Nevro in a research report on Tuesday, November 12th. Citigroup decreased their target price on shares of Nevro from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Wednesday, December 11th. JMP Securities reissued a "market perform" rating on shares of Nevro in a report on Tuesday, November 12th. Wells Fargo & Company decreased their target price on shares of Nevro from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Finally, Robert W. Baird raised their target price on shares of Nevro from $5.00 to $6.00 and gave the company a "neutral" rating in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $6.43.
Get Our Latest Research Report on NVRO
About Nevro
(
Get Free Report)
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.
Read More
Before you consider Nevro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nevro wasn't on the list.
While Nevro currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
